<DOC>
	<DOCNO>NCT01507558</DOCNO>
	<brief_summary>The purpose study test dexamethasone , anti-inflammatory medication approve US Food Drug Administration ( FDA ) , inject safely tissue around blood vessel wall time angioplasty atherectomy .</brief_summary>
	<brief_title>Dexamethasone Infusion Adventitia Enhance Clinical Efficacy After Femoropopliteal Revascularization</brief_title>
	<detailed_description>This investigator-initiated , single-arm , external pilot study assess safety feasibility perivascular administration dexamethasone follow endovascular superficial femoral popliteal artery angioplasty atherectomy . Although dexamethasone approve FDA injection blood , skin joint , approve FDA injection around blood vessel . The investigator want find procedure help prevent re-narrowing blood vessel angioplasty atherectomy . The dexamethasone inject Bullfrog® Micro-Infusion catheter , FDA-approved device inject medication tissue around blood vessel wall . The Bullfrog® Micro-Infusion catheter similar balloon tip catheter except contains microneedle cover fold semi-rigid balloon . Once balloon inflate , microneedle uncovered medication inject tissue around blood vessel .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient &gt; 40 year &lt; 80 year age Patient severe , lifestylelimiting claudication critical limb ischemia ( Rutherford classification 36 ) Patient TASC II A , B C disease , SFA revascularization prefer medical management , endovascular approach preferred revascularization strategy Patient rest ABI &lt; 0.9 abnormal treadmill ABI . Patients incompressible artery must TBI &lt; 0.8 Patient least 1 infrapopliteal runoff vessel patency ankle without &gt; 50 % stenosis Successful cross lesion guidewire successful atherectomy angioplasty residual stenosis &lt; 30 % compare reference vessel Atherectomy procedure result embolization , arteriovenous fistula perforation Patient agree return clinical assessment duplex ultrasound 1 , 3 , 6 , 9 , 12 24 month ( routine clinical care ) Patient simultaneously participate another investigational drug device study Patient pregnant breastfeeding Patient cancer , autoimmune disease , bone marrow organ transplant , concurrent medical illness require immunosuppressive therapy Patient endstage renal disease chronic kidney disease ( eGFR &lt; 30 ) Patient active infection Patient know hypersensitivity contraindication heparin , contrast agent , excipients Dexamethasone Sodium Phosphate Injection , USP , dexamethasone , glucocorticoid Patient life expectancy le one year</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Femoral popliteal lesion</keyword>
</DOC>